Systematic Review |
Intravenous thrombolysis in stroke patients of 
80 versus <80 years of age—a systematic review across cohort studies
Department of Neurology, University Hospital Basel, Basel, Switzerland
Address correspondence to: S. T. Engelter. Fax: (+41) 61 265 5644. Email: sengelter{at}uhbs.ch
Objective: elderly stroke patients were excluded or underrepresented in the randomised controlled trials of intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) applied within 3 h. Cohort studies comparing intravenous rtPA in stroke patients of 
80 versus <80 years of age were limited by small sample sizes and yielded conflicting results. Thus, we performed a systematic review across all such studies.
Methods: a systematic literature search (PubMed; Science Citation Index) was performed to retrieve all eligible studies. Two reviewers independently extracted data on ‘death’, ‘favourable 3-month outcome (modified Rankin Scale 
1)’ and ‘symptomatic intracranial haemorrhage (sICH)’. Across studies, weighted odds ratios (ORs) with 95% confidence intervals (95% CI) were calculated.
Results: six studies were included [n = 2,244 patients; 477 (21%) aged 80 years]. Significant differences in baseline characteristics to the disadvantage of older patients were present in all studies. Compared with younger patients, older patients had a 3.09-time (95% CI = 2.37–4.03; P < 0.001) higher 3-month mortality and were less likely to regain a ‘favourable outcome’ (OR = 0.53; 95% CI = 0.42–0.66; P<0.001). The likelihood for ‘sICH’ (OR = 1.22; 95% CI = 0.77–1.94; P = 0.34) was similar in both age groups.
Conclusion: intravenous rtPA-treated stroke patients of 80 years of age have a less favourable outcome than younger ones. Imbalances in predictive baseline variables to the disadvantage of the older patients may contribute to this finding. Compared with the younger cohort, rtPA-treated stroke patients aged 80 years do not seem exceedingly prone to sICH. Thus, there is scope for benefit from thrombolysis for the older age group. Hence, to obtain reliable evidence on the balance of risk and benefit of intravenous rtPA for stroke patients aged 80 years, it is safe and reasonable to include such patients in randomised placebo-controlled trials.
Keywords: thrombolysis, stroke, elderly, ageing, outcome, systematic review
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Muangpaisan, J. L. Hinkle, M. Westwood, J. Kennedy, and A. M. Buchan Stroke in the very old: clinical presentations and outcomes Age Ageing, July 1, 2008; 37(4): 473 - 475. [Full Text] [PDF]
|
|
|
|
 |
|
 B R Thanvi, S Treadwell, and T Robinson Haemorrhagic transformation in acute ischaemic stroke following thrombolysis therapy: classification, pathogenesis and risk factors Postgrad. Med. J., July 1, 2008; 84(993): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Meseguer, J. Labreuche, J. M. Olivot, H. Abboud, P. C. Lavallee, O. Simon, L. Cabrejo, A. Echeverria, I. F. Klein, M. Mazighi, et al. Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review Age Ageing, January 1, 2008; 37(1): 107 - 111. [Full Text] [PDF]
|
|
|
|
|
|
M. Uyttenboogaart, E. M. C. Schrijvers, P. C. Vroomen, J. De Keyser, and G.-J. Luijckx Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience Age Ageing, September 1, 2007; 36(5): 577 - 579. [Full Text] [PDF]
|
|
|
|
 |
|
 J. De Keyser, Z. Gdovinova, M. Uyttenboogaart, P. C. Vroomen, and G. J. Luijckx Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations Stroke, September 1, 2007; 38(9): 2612 - 2618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dirks, L. W Niessen, P. J Koudstaal, C. L Franke, R. J van Oostenbrugge, D. W J Dippel, and the members of the Delphi panel on indications and Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study J. Neurol. Neurosurg. Psychiatry, July 1, 2007; 78(7): 685 - 689. [Abstract] [Full Text] [PDF]
|
|